SARS-CoV-2 Main Protease Inhibitors That Leverage Unique Interactions with the Solvent Exposed S3 Site of the Enzyme
Open Access
- 20 May 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 15 (6) , 950-957
Abstract
The main protease (MPro) of SARS-CoV-2 is crucial for the virus's replication and pathogenicity. Its active site is characterized by four distinct pockets (S1, S2, S4, and S1-3') and a solvent-exposed S3 site for accommodating a protein substrate. During X-ray crystallographic analyses of MPro bound with dipeptide inhibitors containing a flexible N-terminal group, we often observed an unexpected binding mode. Contrary to the anticipated engagement with the deeper S4 pocket, the N-terminal group frequently assumed a twisted conformation, positioning it for interactions with the S3 site and the inhibitor component bound at the S1 pocket. Capitalizing on this observation, we engineered novel inhibitors to engage both S3 and S4 sites or to adopt a rigid conformation for selective S3 site binding. Several new inhibitors demonstrated high efficacy in MPro inhibition. Our findings underscore the importance of the S3 site's unique interactions in the design of future MPro inhibitors as potential COVID-19 therapeutics.Keywords
Funding Information
- Welch Foundation (A-1715, A-2174)
- Basic Energy Sciences (DE-AC02-05CH11231)
- Division of Microbiology and Infectious Diseases (R21AI164088)
- National Institute of Biomedical Imaging and Bioengineering (R21EB032983)
- Texas A and M University
- Cancer Prevention and Research Institute of Texas (RP210043)
- National Institute of General Medical Sciences (P30GM124169-01, R35GM145351)
This publication has 35 references indexed in Scilit:
- Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitorsAntiviral Research, 2024
- A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antiviralsEuropean Journal of Medicinal Chemistry, 2022
- A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antiviralsEuropean Journal of Medicinal Chemistry, 2022
- 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 AgentsJournal of Medicinal Chemistry, 2021
- A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors**ChemMedChem, 2020
- Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19Journal of Medicinal Chemistry, 2020
- The Architecture of SARS-CoV-2 TranscriptomeCell, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoVChemBioChem, 2020
- On the size of the active site in proteases. I. PapainBiochemical and Biophysical Research Communications, 1967